Commentary

Acromegaly: The New Jan Brady?


 

Diabetes got a lot of the attention at the annual meeting of the American Association of Clinical Endocrinologists in San Diego, and with good reason. We know that diabetes research is important.

But a clinical endocrinology meeting is about more than diabetes. Other studies presented here focused on the endocrine conditions that don’t usually make the front pages in the mainstream media, but the research represents work that is equally important to the clinicians who have made these conditions the focus of their careers, as well as to the patients those physicians hope to help.

Photo credit: Elsevier

Is acromegaly the Jan Brady of endocrinology?

Take acromegaly, a condition caused by abnormal production of growth hormone that causes various tissues in the body to enlarge. Acromegaly occurs in 6 of 100,000 adults, according to the website of the National Library of Medicine.

This condition isn’t nearly as common as diabetes, but this year’s AACE meeting highlighted some hope for these patients. A drug called octreotide helps acromegaly patients by controlling the release of growth hormone, but the current standard treatment involves monthly injections. Preliminary data presented at the meeting showed that an octreotide hydrogel implant can provide steady release of the drug for 6 months, which would make a real difference in the quality of life of these patients.

Other common endocrine disorders got their day in the sun in San Diego: thyroid and parathyroid disorders were featured in hot topics sessions, and a general session was dedicated to a review of recent guidelines for managing osteoporosis.

Photo credit: Flickr user Roadsidepictures (Creative Commons)

Top row, left: Marcia Brady, the eldest sister. Center row, left: Jan Brady, the middle sister.

And, “Medical Therapy for Acromegaly” got its own general session. But wait, there’s more. The AACE is issuing new clinical practice guidelines for the diagnosis and treatment of acromegaly later this year.

If diabetes is the Marcia Brady of endocrinology, perhaps acromegaly is Jan, but it looks like this year she’s coming out of Marcia’s shadow.

–Heidi Splete (on Twitter @hsplete)

Recommended Reading

IDF Backs Bariatric Surgery for Type 2 Diabetes
MDedge Internal Medicine
Dosing Growth Hormone to IGF-I Levels Found Effective, Efficient
MDedge Internal Medicine
New AACE Guidelines Emphasize Comprehensive Diabetes Management
MDedge Internal Medicine
WHI: Unopposed Estrogen Doesn't Raise or Cut Most Risks
MDedge Internal Medicine
ARB, CCB Both Help Prevent Events in Hypertensive Diabetes Patients
MDedge Internal Medicine
Guideline for Treating Diabetic Nerve Pain Unveiled
MDedge Internal Medicine
Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment
MDedge Internal Medicine
Testosterone Replacement Associated with Lower Mortality in Type 2 Diabetes
MDedge Internal Medicine
Clinical Presentation May Determine Costs in Critical Limb Ischemia
MDedge Internal Medicine
Liraglutide Beats Other Therapies for Lowering HbA1c Levels
MDedge Internal Medicine